3
|
Maimaitiyiming Y, Wang QQ, Yang C, Ogra Y, Lou Y, Smith CA, Hussain L, Shao YM, Lin J, Liu J, Wang L, Zhu Y, Lou H, Huang Y, Li X, Chang KJ, Chen H, Li H, Huang Y, Tse E, Sun J, Bu N, Chiou SH, Zhang YF, Hua HY, Ma LY, Huang P, Ge MH, Cao FL, Cheng X, Sun H, Zhou J, Vasliou V, Xu P, Jin J, Bjorklund M, Zhu HH, Hsu CH, Naranmandura H. Hyperthermia Selectively Destabilizes Oncogenic Fusion Proteins. Blood Cancer Discov 2021; 2:388-401. [PMID: 34661159 PMCID: PMC8513904 DOI: 10.1158/2643-3230.bcd-20-0188] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2020] [Revised: 03/09/2021] [Accepted: 04/27/2021] [Indexed: 11/16/2022] Open
Abstract
The PML/RARα fusion protein is the oncogenic driver in acute promyelocytic leukemia (APL). Although most APL cases are cured by PML/RARα-targeting therapy, relapse and resistance can occur due to drug-resistant mutations. Here we report that thermal stress destabilizes the PML/RARα protein, including clinically identified drug-resistant mutants. AML1/ETO and TEL/AML1 oncofusions show similar heat shock susceptibility. Mechanistically, mild hyperthermia stimulates aggregation of PML/RARα in complex with nuclear receptor corepressors leading to ubiquitin-mediated degradation via the SIAH2 E3 ligase. Hyperthermia and arsenic therapy destabilize PML/RARα via distinct mechanisms and are synergistic in primary patient samples and in vivo, including three refractory APL cases. Collectively, our results suggest that by taking advantage of a biophysical vulnerability of PML/RARα, thermal therapy may improve prognosis in drug-resistant or otherwise refractory APL. These findings serve as a paradigm for therapeutic targeting of fusion oncoprotein-associated cancers by hyperthermia. SIGNIFICANCE Hyperthermia destabilizes oncofusion proteins including PML/RARα and acts synergistically with standard arsenic therapy in relapsed and refractory APL. The results open up the possibility that heat shock sensitivity may be an easily targetable vulnerability of oncofusion-driven cancers.See related commentary by Wu et al., p. 300.
Collapse
Affiliation(s)
- Yasen Maimaitiyiming
- Department of Hematology of First Affiliated Hospital, and Department of Public Health, Zhejiang University School of Medicine, Hangzhou, China
- Women's Hospital, Institute of Genetics, and Department of Environmental Medicine, Zhejiang University School of Medicine, Hangzhou, China
- Zhejiang Laboratory for Systems and Precision Medicine, Zhejiang University Medical Center, Hangzhou, China
| | - Qian Qian Wang
- Department of Hematology of First Affiliated Hospital, and Department of Public Health, Zhejiang University School of Medicine, Hangzhou, China
- Zhejiang Laboratory for Systems and Precision Medicine, Zhejiang University Medical Center, Hangzhou, China
| | - Chang Yang
- Department of Hematology of First Affiliated Hospital, and Department of Public Health, Zhejiang University School of Medicine, Hangzhou, China
- Zhejiang Laboratory for Systems and Precision Medicine, Zhejiang University Medical Center, Hangzhou, China
| | - Yasumitsu Ogra
- Department of Toxicology, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan
| | - Yinjun Lou
- Department of Hematology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Clayton A. Smith
- Blood Disorders and Cellular Therapies Center, University of Colorado Hospital, Denver, Colorado
| | - Liaqat Hussain
- Department of Hematology of First Affiliated Hospital, and Department of Public Health, Zhejiang University School of Medicine, Hangzhou, China
| | - Yi Ming Shao
- Department of Pharmacology, Inner Mongolia Medical University, Hohhot, China
| | - Jiebo Lin
- Women's Hospital, Institute of Genetics, and Department of Environmental Medicine, Zhejiang University School of Medicine, Hangzhou, China
| | - Jinfeng Liu
- Women's Hospital, Institute of Genetics, and Department of Environmental Medicine, Zhejiang University School of Medicine, Hangzhou, China
| | - Lingfang Wang
- Women's Hospital, Institute of Genetics, and Department of Environmental Medicine, Zhejiang University School of Medicine, Hangzhou, China
| | - Yong Zhu
- Department of Environmental Sciences, Yale University School of Public Health, New Haven, Connecticut
| | - Haiyan Lou
- Department of Hematology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Yuan Huang
- Zhejiang Province Lishui Municipal Hospital, Lishui, China
| | - Xiaoxia Li
- Department of Hematology, the First Affiliated Hospital, Harbin Medical University, Harbin, China
| | - Kao-Jung Chang
- Institute of Clinical Medicine, National Yang Ming University, Taipei, Taiwan, China
| | - Hao Chen
- Division of Newborn Medicine and Program in Epigenetics, Children's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Hongyan Li
- Department of Chemistry, the University of Hong Kong, Hong Kong, China
| | - Ying Huang
- Institute of Genetics, Zhejiang University, and Department of Genetics, School of Medicine, Zhejiang University, Hangzhou, China
| | - Eric Tse
- Department of Medicine, the University of Hong Kong and Queen Mary Hospital, Hong Kong, China
| | - Jie Sun
- Department of Hematology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Na Bu
- Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
| | - Shih-Hwa Chiou
- Taipei Veterans General Hospital Department of Medical Research, Taipei, Taiwan, China
| | - Yan Fang Zhang
- Department of Hematology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | | | - Li Ya Ma
- Department of Hematology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Ping Huang
- Zhejiang Provincial People's Hospital, Hangzhou, China
| | - Ming Hua Ge
- Zhejiang Provincial People's Hospital, Hangzhou, China
| | - Feng-Lin Cao
- Department of Hematology, the First Affiliated Hospital, Harbin Medical University, Harbin, China
| | - Xiaodong Cheng
- Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
| | - Hongzhe Sun
- Department of Chemistry, the University of Hong Kong, Hong Kong, China
| | - Jin Zhou
- Department of Hematology, the First Affiliated Hospital, Harbin Medical University, Harbin, China
| | - Vasilis Vasliou
- Department of Environmental Sciences, Yale University School of Public Health, New Haven, Connecticut
| | - Pengfei Xu
- Institute of Genetics, Zhejiang University, and Department of Genetics, School of Medicine, Zhejiang University, Hangzhou, China
| | - Jie Jin
- Department of Hematology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Mikael Bjorklund
- Zhejiang University–University of Edinburgh Institute, Zhejiang University School of Medicine, Hangzhou, China
| | - Hong-Hu Zhu
- Zhejiang Laboratory for Systems and Precision Medicine, Zhejiang University Medical Center, Hangzhou, China
- Department of Hematology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
| | - Chih-Hung Hsu
- Women's Hospital, Institute of Genetics, and Department of Environmental Medicine, Zhejiang University School of Medicine, Hangzhou, China
| | - Hua Naranmandura
- Department of Hematology of First Affiliated Hospital, and Department of Public Health, Zhejiang University School of Medicine, Hangzhou, China
- Zhejiang Laboratory for Systems and Precision Medicine, Zhejiang University Medical Center, Hangzhou, China
| |
Collapse
|
4
|
Abstract
Cell division is essential for organismal growth and tissue homeostasis. It is exceptionally significant in tissues chronically exposed to intrinsic and external damage, like the liver. After decades of studying the regulation of cell cycle by extracellular signals, there are still gaps in our knowledge on how these two interact with metabolic pathways in vivo. Studying the cross-talk of these pathways has direct clinical implications as defects in cell division, signaling pathways, and metabolic homeostasis are frequently observed in liver diseases. In this review, we will focus on recent reports which describe various functions of cell cycle regulators in hepatic homeostasis. We will describe the interplay between the cell cycle and metabolism during liver regeneration after acute and chronic damage. We will focus our attention on non-alcoholic fatty liver disease, especially non-alcoholic steatohepatitis. The global incidence of non-alcoholic fatty liver disease is increasing exponentially. Therefore, understanding the interplay between cell cycle regulators and metabolism may lead to the discovery of novel therapeutic targets amenable to intervention.
Collapse
Affiliation(s)
- Matias J Caldez
- WPI Immunology Frontiers Research Centre, Osaka University, 3-1 Yamadaoka, Suita, Osaka, 565-0871, Japan.
| | - Mikael Bjorklund
- Zhejiang University-University of Edinburgh (ZJU-UoE) Institute and 2nd Affiliated Hospital, Zhejiang University School of Medicine, 718 East Haizhou Rd., Haining, 314400, Zhejiang, People's Republic of China
| | - Philipp Kaldis
- Department of Clinical Sciences, Clinical Research Centre (CRC), Lund University, Box 50332, 202 13, Malmö, Sweden.
| |
Collapse
|